Novel Therapeutics in Glaucoma Management.
Novel Therapeutics in Glaucoma Management.
复制标题
青光眼管理的新疗法。
DOI：
10.2174/1570159x15666170915142727
复制
发表时间：
2018
影响因子：
5.3
通讯作者：
Uva M
中科院分区：
文献类型：
--
作者：
Bucolo C;Platania CBM;Drago F;Bonfiglio V;Reibaldi M;Avitabile T;Uva M
青光眼是一种以视网膜神经节细胞死亡和视野改变为特征的进行性视神经病变。眼内压（IOP）升高被认为是青光眼的主要危险因素，即使不能排除其他因素，如表观遗传机制。 概述了最终有前途的实验药物来管理青光眼。 特别是，我们专注于嘌呤能配体，KATP通道激活剂，气体（一氧化氮，一氧化碳和硫化氢），非糖皮质激素类固醇化合物，神经营养因子，PI 3 K/Akt激活剂，胞磷胆碱，组蛋白脱乙酰酶抑制剂，大麻素，多巴胺和5-羟色胺受体配体，小干扰RNA和Rho激酶抑制剂。 该综述还被赋予了一个简短的章节，介绍了市场上已经存在的抗青光眼药物的潜在神经保护益处的最新报告。
Glaucoma is a progressive optic neuropathy characterized by retinal ganglion cell death and altera-tions of visual field. Elevated intraocular pressure (IOP) is considered the main risk factor of glaucoma, even though other factors cannot be ruled out, such as epigenetic mechanisms. An overview of the ultimate promising experimental drugs to manage glaucoma has been provided. In particular, we have focused on purinergic ligands, KATP channel activators, gases (nitric oxide, carbon monoxide and hydrogen sulfide), non-glucocorticoid steroidal compounds, neurotrophic factors, PI3K/Akt activators, citicoline, histone deacetylase inhibitors, cannabinoids, dopamine and serotonin receptors ligands, small interference RNA, and Rho kinase in-hibitors. The review has been also endowed of a brief chapter on last reports about potential neuroprotective benefits of anti-glaucoma drugs already present in the market.